martes, 30 de junio de 2020

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus | Moderna, Inc.

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus | Moderna, Inc.

The Readout

Damian Garde & Meghana Keshavan

When are we getting that coronavirus vaccine data?

Speaking of long-awaited data, we still don’t know just how well Moderna’s investigational coronavirus vaccine works.

As you might recall, Moderna issued a press release worth $1.3 billion that described, in qualitative terms, the early returns from its vaccine. The full data would be published in a matter of “weeks, not months,” Moderna CEO Stéphane Bancel said one month and two weeks ago.

The timing depends not on Moderna but on its partners at the NIH, which ran the Phase 1 study. An NIH spokeswoman said there's no set timeline for publication. But there’s more than a little immediacy. Some time in July, Moderna plans to start enrolling about 30,000 people in a Phase 3 trial. As it stands, those potential volunteers have only a press release of information to go on.

No hay comentarios: